In a 2020 study, lipid–albumin nanoparticles engineered to release paclitaxel in response to FAPα demonstrated enhanced tumor penetration and robust tumor regression in a pancreatic cancer mouse model, with minimal systemic toxicity [193]. The gene discussed is FAP; the disease is familial pancreatic carcinoma.